WHWK
Whitehawk Therapeutics Inc NASDAQ Listed Aug 1, 2017$3.74
-3.11%
vs $3.86
Mkt Cap $213.2M
52w Low $1.82
52.2% of range
52w High $5.50
50d MA $4.29
200d MA $3.73
P/E (TTM)
-3.3x
EV/EBITDA
—
P/B
1.7x
Debt/Equity
0.0x
ROE
-15.1%
P/FCF
-2.4x
RSI (14)
18.80
ATR (14)
$0.19
Beta
0.62
50d MA
$4.29
200d MA
$3.73
Avg Volume
311.8K
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
17383 Sunset Blvd, Suite A250 · Pacific Palisades, CA 90272 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | BMO | -0.30 | -0.20 | +32.4% | 4.07 | +0.5% | +15.5% | +1.3% | -4.4% | +2.6% | +0.9% | — |
| May 7, 2026 | BMO | -0.36 | -0.32 | +11.1% | 4.15 | -0.2% | -5.1% | +0.8% | -4.3% | +3.2% | +25.8% | — |
| Mar 12, 2026 | BMO | -0.55 | -0.34 | +38.2% | 3.90 | +0.3% | +0.3% | -0.3% | +1.3% | -3.5% | -5.8% | — |
| Nov 6, 2025 | BMO | -0.51 | -0.26 | +49.0% | 2.10 | +0.0% | -1.4% | +5.3% | +2.3% | +0.0% | -6.3% | — |
| Aug 7, 2025 | BMO | 0.49 | -0.76 | -255.1% | 1.72 | +0.0% | +1.7% | -3.4% | +1.2% | +0.0% | -5.3% | — |
| May 8, 2025 | BMO | -0.46 | -0.36 | +21.7% | 1.64 | +6.1% | +3.7% | -1.8% | -1.2% | +1.8% | +0.6% | — |
| Mar 18, 2025 | BMO | -0.22 | -0.67 | -204.5% | 2.05 | -13.7% | -1.5% | -3.0% | +4.6% | -3.4% | -1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 13 | Leerink Partners | Initiates | Outperform | $9 | $3.97 | $4.00 | +0.8% | -3.3% | -0.8% | +1.0% | +1.0% | +0.0% |
| Jun 25 | B. Riley Securities | Initiates | Buy | $10 | $4.39 | $4.53 | +3.2% | -6.4% | +1.2% | +6.0% | +3.9% | -6.1% |
No insider trades available.
8-K
Whitehawk Therapeutics Inc -- 8-K Filing
May 21
8-K · 1.01
! Medium
Whitehawk Therapeutics Inc -- 8-K 1.01: Equity Issuance
May 13
8-K · 2.02
!! High
Whitehawk Therapeutics Inc -- 8-K 2.02: Earnings Results
Whitehawk Therapeutics reported Q1 2026 earnings results, providing investors with updated financial performance metrics and operational updates for the quarter ending March 31, 2026.
May 7
8-K
Unknown — 8-K Filing
Whitehawk's rebranding and focus on next-generation ADC cancer treatments signal strategic repositioning; investors should monitor clinical progress and capital runway, as clinical-stage biotech success depends on trial outcomes and funding availability.
Mar 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Siren, L.l.c. | 2,337,102 | $11M | New | Jun 2026 |
| 2 | Avoro Capital Advisors Llc | 2,849,402 | $10M | — | Mar 2026 |
| 3 | Blackrock, Inc. | 1,922,828 | $9M | New | Jun 2026 |
| 4 | Yu Fan | 2,070,000 | $7M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 1,388,561 | $6M | Added | Jun 2026 |
| 6 | Stempoint Capital Lp | 939,369 | $3M | New | Mar 2026 |
| 7 | Ally Bridge Group (Ny) Llc | 817,939 | $3M | New | Mar 2026 |
| 8 | Renaissance Technologies Llc | 413,822 | $2M | Reduced | Jun 2026 |
| 9 | Millennium Management Llc | 380,406 | $2M | Added | Jun 2026 |
| 10 | Two Sigma Investments, Lp | 296,612 | $1M | Added | Jun 2026 |
| 11 | Vanguard Portfolio Management Llc | 219,217 | $1M | New | Jun 2026 |
| 12 | Woodline Partners Lp | 281,497 | $971K | New | Mar 2026 |
| 13 | Susquehanna International Group, Llp | 203,465 | $702K | Added | Mar 2026 |
| 14 | Adar1 Capital Management, Llc | 128,503 | $443K | New | Mar 2026 |
| 15 | Verdad Advisers, Lp | 115,484 | $398K | New | Mar 2026 |
| 16 | Northern Trust Corp | 107,266 | $370K | Added | Mar 2026 |
| 17 | Citadel Advisors Llc | 60,172 | $276K | Reduced | Jun 2026 |
| 18 | Point72 Asset Management, L.p. | 57,129 | $262K | Added | Jun 2026 |
| 19 | Acadian Asset Management Llc | 70,101 | $239K | Added | Mar 2026 |
| 20 | Nuveen, Llc | 43,799 | $201K | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 19
All ↗
Valuation
Market Cap
$213.2M
Enterprise Value
$85.8M
P/E (TTM)
-3.34x
Forward P/E
—
PEG Ratio
0.08x
P/B
1.70x
P/S
—
P/FCF
-2.36x
EV/EBITDA
—
Shares Out
61.9M
Financials (TTM)
Revenue
$0
Net Income
-$79.8M
EBITDA
-$81.3M
Free Cash Flow
-$98.0M
Op Cash Flow
-$97.4M
EPS Basic
$-0.33
EPS Diluted
$-1.12
EPS Forward
$-1.32
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$150.8M
Total Liab.
$14.5M
Total Equity
$136.3M
Cash
$145.7M
LT Debt
$0
Book Value/Sh
$2.20
Debt/Equity
0.00x
Current Ratio
10.26
Quick Ratio
10.26
Returns & Growth
ROE
-15.1%
ROA
-13.7%
ROIC
-83.9%
Rev Growth YoY
-72.5%
EPS Growth YoY
+86.0%
Price Returns
2W
-9.0%
1M
-22.7%
3M
-10.1%
6M
+4.8%
12M
+92.8%
Technicals
52W High
$5.50
52W Low
$1.82
50d MA
$4.29
200d MA
$3.73
RSI (14)
18.80
ATR (14)
$0.19
Beta
0.62
Avg Volume
312K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 27, 2026 9:21am
· Source: financialmodelingprep.com